+44 (0) 1865 234904
Please note that these are academic contact details and should not be used for clinical correspondence.
Prof Gabriele DeLuca is Professor of Clinical Neurology and Experimental Neuropathology, Honorary Consultant Neurologist, and Director of Clinical Neurosciences Undergraduate Education at the University of Oxford. He has established an internationally recognised research group focused on the neuropathology of multiple sclerosis and other inflammatory and neurodegenerative diseases. His research work has resulted in numerous publications and awards, including the prestigious Cavanagh Prize awarded by the British Neuropathological Society and Fellowship of the Royal College of Pathologists.
He works with the Concussion Legacy Foundation to lead the Concussion Legacy Project, a brain bank for elite athletes and veterans, and is a member of the Brain Health advisory board of the Professional Footballers Association.
He is the inaugural chair of Leadership University at the American Academy of Neurology, co-leads the MS Leadership Academy in the UK, and has been named an Oxford University Hospitals ‘Champion for Change.’
M.D., D.Phil., FRCPath, FAAN
Professor of Clinical Neurology and Experimental Neuropathology
- Director of Clinical Neurosciences Undergraduate Education
- Honorary Consultant Neurologist
Neuropathology of Neurodegeneration and Inflammation
Prof De Luca's research group explores the neuropathology of multiple sclerosis and other inflammatory and neurodegenerative diseases, including dementia, traumatic brain injury, and vascular disease using a multidisciplinary team approach to post-mortem brain and spinal cord tissue. The aim is that the understanding derived from these studies will translate into the identification of targets for living patients for therapeutic benefit.
Prof De Luca is passionate about integrating neurology and rehabilitation clinical care and research for chronic brain diseases, such as multiple sclerosis and traumatic brain injury. He leads a partnership between Oxford and Quinnipiac University and Trinity Health of New England, USA, with the aim to revolutionise the delivery of clinical care, research, and education in neuro-rehabilitation and become a world-leading centre of excellence in restorative neuroscience.
In addition, Prof De Luca is a leader in education at Oxford Medical School where he is Director of Clinical Neurosciences Undergraduate Education. He is dedicated to delivering the highest standard of neurology education at Oxford and has led two successful transformations of the Clinical Neurosciences teaching programme.
Sources of Funding
- UK MS Society (2023-2026)
- Strategic Innovation Fund, University of Oxford (2023-2025)
- Bristol Myers Squibb (2021-2024)
- Department of Defense, US Government (2021-2023)
- Oxford-Quinnipiac Partnership (2020-2025)
- National Health and Medical Research Council Project Grant (2019-2023)
- UK MS Society Project Grant (2019-2023)
- Medical Research Council (MRC) Project Grant (2015-2019)
- Grant for Multiple Sclerosis Innovation, Merck Serono (2016-2019)
- Medical Research Council (MRC) Doctoral Training Programme (2012 - 2016)
- Biomedical Research Centre (BRC), NIHR Oxford (2012 - 2016)
- Alzheimer's Research UK, Oxford (2014)
- John Fell Fund, University of Oxford (2013-2014)
- Goodger Scholarship, University of Oxford (2011 - 2014)
- AAN/CMSC John F. Kurtzke Clinician Scientist Fellowship (2010-2013)
Selected Recent Awards
2022 - Teaching Excellence Award, Medical Sciences Division (University of Oxford)
2020 - Fellow of the American Academy of Neurology (FAAN)
2020 - A.B. Baker Teacher Recognition Award (AAN)
2019 - Fellow of the Royal College of Pathologists (FRCPath)
2017 - Cavanagh Prize (British Neuropathological Society)
2016 - Young Alumni Award (The University of Western Ontario)
2015 - Leader of Tomorrow (Oxford University Hospitals NHS Foundation Trust)
2015 - Emerging Leader (American Academy of Neurology)
Tuberous Sclerosis Complex-1 (TSC1) contributes to selective neuronal vulnerability in Alzheimer's Disease.
Adriaanse BA. et al, (2023), Neuropathol Appl Neurobiol
Microglia directly associate with pericytes in the central nervous system.
Morris GP. et al, (2023), Glia
Identification of early neurodegenerative pathways in progressive multiple sclerosis.
Kaufmann M. et al, (2022), Nat Neurosci
Quantification of upper limb dysfunction in the activities of the daily living in persons with multiple sclerosis.
Pisa M. et al, (2022), Mult Scler Relat Disord, 63
Anterior optic pathway pathology in CNS demyelinating diseases.
Pisa M. et al, (2022), Brain